跳至主要内容
临床试验/NCT06695273
NCT06695273尚未招募不适用

Using Retinal Photograph Based AI to Predict Incident Coronary Heart Disease

Tsinghua University0 个研究点目标入组 1,570 人开始时间: 2025年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
1,570
主要终点
Accuracy

研究概览

简要总结

To determine whether an integrated retinal AI decision support can improve predictive accuracy of coronary heart disease (CHD), the investigators are conducting a randomized controlled study of AI guided prediction of CHD compared to clinical prediction by physicians (e.g., usingPCEs), both using clinical intuition as baseline.

详细描述

This is a randomized controlled trial (RCT) evaluating the effectiveness of an AI-based decision support tool in CHD risk prediction and decision making by physicians. Prospective cohort study participant cases will be randomly assigned to either guideline group (e.g., PCEs) or AI group after baseline assessment (clinical intuition):

There are three settings: (1) Clinical Intuition (baseline assessment) Physicians' make decision about prevention strategy initiation (e.g., statin initiation) without any external assistance. Assessment relies solely on the physician's clinical judgment and experience. (2) Guideline-Based Group (Guideline Group) Physicians use a PCE table to calculate the 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making. (3) AI-Assisted Group (AI Group) Physicians receive CHD probability estimates from an AI model based on retinal photographs. The AI tool provides individualized obstructive CHD probabilities, leveraging retinal biomarkers associated with cardiovascular risk.

Primary Objective To evaluate whether AI-guided decision support could improves diagnostic accuracy of CHD to a greater extent than standard clinical assessments, both compared to clinical intuition. The accuracy could be assessed by the extent of prevention initiation (e.g., prescribing statins) corresponding with actual CHD outcomes observed.

Secondary Objective To assess whether AI-guided decision support reduces the time required to complete CHD assessments and decision making.

Participants, Readers and Randomization:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individuals without uncontrolled vascular risk factors
  • Age range: 40-75 years old
  • Can accept and cooperate with the examination and potential follow-up work after being selected for clinical trials

排除标准

  • Severe lung disease and cancer or surgery patients
  • Statin user or pre-existing cardiovascular disease
  • Individuals with severe liver and kidney dysfunction and electrolyte imbalance

结局指标

主要结局

Accuracy

时间窗: Through study completion, an average of 1 week

To evaluate whether AI-guided decision support could improves diagnostic accuracy of CHD to a greater extent than standard clinical assessments, both compared to clinical intuition. The accuracy could be assessed by the degree to which prevention initiation (e.g., prescribing statins) align with actual CHD outcomes observed.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Tien Yin Wong

Professor

Tsinghua University

相似试验